Microvast's Record Revenue Tempered by Operational Headwinds

Microvast's record 2025 revenue fell short of projections due to South Korean regulations and European project delays. Focus shifts to China expansion and Iveco partnership.

Battery technology firm Microvast Holdings concluded its 2025 fiscal year by posting record annual revenue, yet the results fell short of the company's own initial projections. The performance was constrained by a combination of regulatory challenges in South Korea and project delays with key customers in Europe. Investor attention is now shifting to the company's capacity expansion plans in Asia and the deepening of its strategic alliance with the Iveco Group.

Strategic Focus Shifts to Asian Expansion and Iveco Partnership

A cornerstone of Microvast's forward strategy involves the expansion of its production facility in Huzhou, China. Following the current ramp-up phase, series production at the site is slated to commence in 2026, aiming to address growing global demand for energy storage solutions. Management anticipates further revenue growth for the current year, though it must navigate complex customs structures to achieve it.

The market has responded positively to the continued collaboration with Iveco, which is expected to extend to next-generation battery technologies in the future. This partnership is viewed as a key strategic asset amid other operational challenges.

Regulatory and Project Delays Dampen Results

Despite achieving a top-line record, Microvast missed its original 2025 forecast. Market analysts attribute this primarily to two factors: stricter regulatory frameworks in South Korea and delays in the ramp-up of new customer platforms within the EMEA region. These headwinds effectively slowed the growth trajectory of the battery specialist.

For investors, liquidity planning remains a point of focus, with a second comparative payment related to Clenera expected on July 15, 2026. Market participants are closely watching whether potential joint venture developments could help cushion these financial obligations. The coming months will be critical in determining if Microvast can recover from the operational delays experienced in Europe.

Technical Rebound Amid a Challenging Year

The financial update prompted a share price increase of nearly eight percent to €1.30 in today's trading. However, the stock remains under significant pressure for the year-to-date period, showing a decline of approximately 45 percent. Technical indicators suggest a cautious outlook, with the Relative Strength Index (RSI) currently reading 72.5, signaling a technically overbought condition.

Key dates for shareholders in the coming months include:

• May 11, 2026: Release of first-quarter 2026 financial results.
• July 15, 2026: Anticipated second comparative payment related to Clenera.

The company's ability to execute on its capacity expansion and manage near-term financial commitments will likely be the dominant themes influencing its performance through 2026.